Therapeutic Response

HER2-negative and PR positive status confers therapeutic sensitivity to Abemaciclib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Verzenio (abemaciclib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.